Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Vascular Diseases & Diabetic Retinopathy II

09:45 - 11:15 | 08 September | Room: Speakers' Corner.

Back to Previous

09:50670nm photobiomodulation modulates bioenergetics and oxidative stress in an in vitro model of diabetic retinopathy
A. Hall USA
09:55Correlation of retinal vein caliber with retinal oxygen saturation level in patients with central retinal vein occlusion
M. Shibuya Japan
10:05Efficacy of ranibizumab plus aflibercept therapy with dexamethosone intravitreal injection in patients with diabetic macular edema
J. Nassaralla Brazil
10:10Micropulse laser in diabetic macular oedema- Is it effective and safe?
S. Gudsoorkar UK
10:15Observation of ranibizumab treatment in real-life conditions – Interim analysis of 630 German patients with retinal vein occlusion (RVO) from the observational, non-interventional PACIFIC-study
M. Grüb Germany
10:20Ozurdex in macular oedema associated with retinal vein occlusion - real world 3 year data from Eastbourne
G. Murphy UK
10:25Pre-operative use of intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery.
S. Kabanarou Greece
10:30Real world experience of intravitreal dexamethasone implant (ozurdex) in diabetic macular oedema
S. Gajree UK
10:30Analysis of retinal layer thickness and choroidal thickness in diabetic macular oedema treated with ranibizumab or aflibercept
S. Oruc Dundar Turkey
10:30Anterograde optic neuropathy and associated retrograde degeneration after branch retinal vein occlusion
S. Yu Switzerland
10:35Real-world evidence of the effectiveness of intravitreal aflibercept in patients with diabetic macular oedema in United Kingdom: Baseline Characteristics of the DRAKO study
J. Talks UK
10:40Real-world outcomes of intravitreal dexamethasone implants in the treatment of macular oedema after retinal vein occlusion
T. Yap UK
10:45Supernormal flicker ergs in eyes with central retinal vein occlusion: clinical characteristics, prognosis, and effects of anti-vegf agent
R. Miyata Japan
10:50Three loading dose plus treat-and-erxtend regimen with ranibizumab for diabetic macular edema – Tri-center one-year real-world results
C. Lin Taiwan
10:55Three-year visual acuity outcomes in patients with macular oedema following retinal vein occlusion treated with anti-vegf therapy - a retrospective cohort study
M. Islam UK
11:00Type 2 diabetes patients treated for diabetic retinopathy are at more than double the risk of renal failure needing hemodialysis: a real-world healthcare claims database in Japan
R. Kawasaki Japan
11:05Сombined surgical treatment for diabetic macular edema
R. Zainullin Russia
Back to Previous

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved